These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 1737353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.
    Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA.
    J Nucl Med; 1995 May; 36(5):746-53. PubMed ID: 7738643
    [Abstract] [Full Text] [Related]

  • 3. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997 May; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 4. Antibody responses to macrocycles in lymphoma.
    DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ.
    J Nucl Med; 1996 Mar; 37(3):451-6. PubMed ID: 8772643
    [Abstract] [Full Text] [Related]

  • 5. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.
    Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
    [Abstract] [Full Text] [Related]

  • 6. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA.
    Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
    [Abstract] [Full Text] [Related]

  • 7. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 8. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.
    Clin Cancer Res; 2005 Aug 15; 11(16):5920-7. PubMed ID: 16115934
    [Abstract] [Full Text] [Related]

  • 9. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec 15; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ, Zhong GR, Salako Q, Li M, DeNardo GL, Meares CF.
    J Nucl Med; 1995 May 15; 36(5):829-36. PubMed ID: 7738660
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL.
    J Nucl Med; 1997 Aug 15; 38(8):1180-5. PubMed ID: 9255145
    [Abstract] [Full Text] [Related]

  • 12. Targeting of tumours with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: immunolocalisation, pharmacokinetics and immune response.
    Kalofonos HP, Kosmas C, Hird V, Snook DE, Epenetos AA.
    Eur J Cancer; 1994 Aug 15; 30A(12):1842-50. PubMed ID: 7880616
    [Abstract] [Full Text] [Related]

  • 13. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 15. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan 01; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 16. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec 01; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

  • 17. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
    Gholipour N, Jalilian AR, Khalaj A, Johari-Daha F, Yavari K, Sabzevari O, Khanchi AR, Akhlaghi M.
    Daru; 2014 Jul 29; 22(1):58. PubMed ID: 25074720
    [Abstract] [Full Text] [Related]

  • 18. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
    Li M, Meares CF, Salako Q, Kukis DL, Zhong GR, Miers L, DeNardo SJ.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
    [Abstract] [Full Text] [Related]

  • 19. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
    DeNardo GL, DeNardo SJ.
    Cancer Biother Radiopharm; 2004 Feb 01; 19(1):85-92. PubMed ID: 15068616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.